A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

被引：0

作者：

Terpos, Evangelos ^{[1
]}

Kastritis, Efstathios ^{[2
]}

Symeonidis, Argiris ^{[3
]}

Pouli, Anastasia ^{[4
]}

Delimpasi, Sosana ^{[5
]}

Katodritou, Eirini ^{[6
]}

Hatzimichael, Eleftheria ^{[7
]}

Ntanasis-Stathopoulos, Ioannis ^{[8
]}

Malandrakis, Panagiotis ^{[8
]}

Fotiou, Despina ^{[8
]}

Migkou, Magdalini ^{[8
]}

Theodorakakou, Foteini ^{[8
]}

Spiliopoulou, Vasiliki ^{[8
]}

Syrigou, Rodanthi ^{[8
]}

Eleutherakis-Papaiakovou, Evangelos ^{[2
]}

Manousou, Kyriaki ^{[9
]}

Gavriatopoulou, Maria

Dimopoulos, Meletios A. ^{[2
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Drosia, Greece

[2] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[3] Univ Patras, Sch Med, Hematol Div, Dept Internal Med, Patras, Greece

[4] St Savvas Oncol Hosp, Hematol Dept, Athens, Greece

[5] Gen Hosp Evangelismos, Athens, Greece

[6] Theagenio Canc Hosp, Dept Hematol, Thessaloniki, Greece

[7] Univ Ioannina, Dept Hematol, Fac Med, Ioannina, Greece

[8] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[9] Hlth Data Specialists, Dublin, Ireland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173185

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[11] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study [J].

Kumar, S. K. ;

Flinn, I. ;

Noga, S. J. ;

Hari, P. ;

Rifkin, R. ;

Callander, N. ;

Bhandari, M. ;

Wolf, J. L. ;

Gasparetto, C. ;

Krishnan, A. ;

Grosman, D. ;

Glass, J. ;

Sahovic, E. A. ;

Shi, H. ;

Webb, I. J. ;

Richardson, P. G. ;

Rajkumar, S. V. .

LEUKEMIA, 2010, 24 (07) :1350-1356

[12] Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study [J].

S K Kumar ;

I Flinn ;

S J Noga ;

P Hari ;

R Rifkin ;

N Callander ;

M Bhandari ;

J L Wolf ;

C Gasparetto ;

A Krishnan ;

D Grosman ;

J Glass ;

E A Sahovic ;

H Shi ;

I J Webb ;

P G Richardson ;

S V Rajkumar .

Leukemia, 2010, 24 :1350-1356

[13] Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ). [J].

Facon, Thierry ;

Dimopoulos, Meletios Athanasios ;

Leleu, Xavier P. ;

Beksac, Meral ;

Pour, Ludek ;

Hajek, Roman ;

Liu, Zhuogang ;

Minarik, Jiri ;

Moreau, Philippe ;

Romejko-Jarosinska, Joanna ;

Spicka, Ivan ;

Vorobyev, Vladimir I. ;

Cavo, Michele ;

Goldschmidt, Hartmut ;

Martin, Thomas G. ;

Manier, Salomon ;

Bregeault, Marie-France ;

Mace, Sandrine ;

Berthou, Christelle ;

Orlowski, Robert Z. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[14] Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI). [J].

Leleu, Xavier P. ;

Hulin, Cyrille ;

Lambert, Jerome ;

Bobin, Arthur ;

Manier, Salomon ;

Perrot, Aurore ;

Jaccard, Arnaud ;

Montes, Lydia ;

Karlin, Lionel ;

Godmer, Pascal ;

Chalopin, Thomas ;

Slama, Borhane ;

Laribi, Kamel ;

Chretien, Marie-Lorraine ;

Mohty, Mohamad ;

Touzeau, Cyrille ;

Moreau, Philippe ;

Avet-Loiseau, Herve ;

Corre, Jill ;

Facon, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[15] Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ) [J].

Facon, Thierry ;

Dimopoulos, Meletios ;

Leleu, Xavier ;

Beksac, Meral ;

Pour, Ludek ;

Hajek, Roman ;

Liu, Zhuogang ;

Minarik, Jiri ;

Moreau, Philippe ;

Romejko-Jarosinska, Joanna ;

Spicka, Ivan ;

Vorobyev, Vladimir ;

Cavo, Michele ;

Goldschmidt, Hartmut ;

Martin, Thomas ;

Manier, Salomon ;

Bregeault, Marie-France ;

Mace, Sandrine ;

Berthou, Christelle ;

Orlowski, Robert .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 :S31-S31

[16] Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). [J].

Ocio, Enrique M. ;

Rodriguez Otero, Paula ;

Bringhen, Sara ;

Oliva, Stefania ;

Nogai, Axel ;

Attal, Michel ;

Moreau, Philippe ;

Martinez-Lopez, Joaquin ;

Le Roux, Nadia ;

Mace, Sandrine ;

Rouchon, Marie-Claude ;

Wang, Qiuyan ;

Mateos, Maria-Victoria .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[17] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study [J].

Askeland, Frida Bugge Bugge ;

Haukas, Einar ;

Slordahl, Tobias S. S. ;

Klostergaard, Anja ;

Alexandersen, Tatjana ;

Lysen, Anna ;

Abdollahi, Pegah ;

Hermansen, Emil ;

Schjesvold, Fredrik .

BLOOD, 2024, 144 :4730-4731

[18] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study [J].

Askeland, Frida Bugge Bugge ;

Haukas, Einar ;

Slordahl, Tobias S. ;

Schjoll, Diana ;

Lysen, Anna ;

Hermansen, Emil ;

Schjesvold, Fredrik .

BLOOD, 2022, 140 :12623-12625

[19] Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study [J].

Askeland, Frida Bugge ;

Haukas, Einar ;

Slordahl, Tobias S. ;

Klostergaard, Anja ;

Alexandersen, Tatjana ;

Schjoll, Diana ;

Lysen, Anna ;

Hermansen, Emil ;

Schjesvold, Fredrik .

BLOOD, 2023, 142

[20] Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment [J].

Jian, Yuan ;

Chang, Long ;

Shi, Ming-Xia ;

Sun, Ying ;

Chu, Xiao-Xia ;

Xue, Hua ;

Huang, Wen-Rong ;

Shen, Xu-Liang ;

Ma, Jie ;

Jia, Guo-Rong ;

Feng, Ya-Qing ;

Xi, Zhen-Fang ;

Zhao, Yan-Hong ;

Ma, Yan-Ping ;

Xiao, Jing ;

Ma, Guang-Yu ;

Wang, Qing-Ming ;

Bao, Li ;

Dong, Yu-Jun ;

Zhou, He-Bing ;

Sun, Chun-Yan ;

Su, Guo-Hong ;

Yan, Yan ;

Qimuge, Sai-Yin ;

Su, Li-Ping ;

Sun, Jing-Nan ;

Tian, Wei-Wei ;

Sun, Xiu-Li ;

Ing, Hong-Mei ;

Gao, Da ;

Chen, Wen-Ming ;

Li, Jian ;

Gao, Wen .

BLOOD ADVANCES, 2023, 7 (24) :7581-7584

← 1 2 3 4 5 →